|
1
|
Paik S, Tang G, Shak S, Kim C, Baker J,
Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Henderson IC and Patek AJ: The
relationship between prognostic and predictive factors in the
management of breast cancer. Breast Cancer Res Treat. 52:261–288.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hayes DF, Trock B and Harris AL: Assessing
the clinical impact of prognostic factors: When is ‘statistically
significant’ clinically useful? Breast Cancer Res Treat.
52:305–319. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagaraj G and Ma CX: Adjuvant chemotherapy
decisions in clinical practice for early-stage node-negative,
estrogen receptor-positive, HER2-negative breast cancer: Challenges
and considerations. J Natl Compr Canc Netw. 11:246–250; quiz 251.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abramovitz M and Leyland-Jones B: A
systems approach to clinical oncology: Focus on breast cancer.
Proteome Sci. 4:52006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duffy MJ: Predictive markers in breast and
other cancers: A review. Clin Chem. 51:494–503. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van De Vijver MJ, He YD, Van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sotiriou C, Neo SY, McShane LM, Korn EL,
Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast
cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee MH, Han W, Lee JE, Kim KS, Park H, Kim
J, Bae SY, Shin HJ, Lee JW and Lee ES: The clinical impact of
21-gene recurrence score on treatment decisions for patients with
hormone receptor-positive early breast cancer in Korea. Cancer Res
Treat. 47:208–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Albain KS, Barlow WE, Shak S, Hortobagyi
GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL,
Davidson NE, et al: Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: A
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA
Jr, et al: Prospective validation of a 21-gene expression assay in
breast cancer. N Engl J Med. 373:2005–2014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Győrffy B, Hatzis C, Sanft T, Hofstatter
E, Aktas B and Pusztai L: Multigene prognostic tests in breast
cancer: Past, present, future. Breast Cancer Res. 17:112015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Waintraub SE, McNamara D, Graham DMA,
Pecora AL, Min J, Wu T, Noh HG, Connors J, Pe Benito R, Choi K, et
al: Real-world economic value of a 21-gene assay in early-stage
breast cancer. Am J Manag Care. 23:e416–e420. 2017.PubMed/NCBI
|
|
15
|
Mamounas EP, Tang G, Fisher B, Paik S,
Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL and
Wolmark N: Association between the 21-gene recurrence score assay
and risk of locoregional recurrence in node-negative, estrogen
receptor-positive breast cancer: Results from NSABP B-14 and NSABP
B-20. J Clin Oncol. 28:1677–1683. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan AC, Li BT, Nahar K, Danieletto S, Fong
ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, et al:
Correlating Ki67 and other prognostic markers with Oncotype DX
recurrence score in early estrogen receptor-positive breast cancer.
Asia Pac J Clin Oncol. 14:e161–e166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Smyth P, Cahill S, Denning K, Flavin
R, Aherne S, Pirotta M, Guenther SM, O'Leary JJ and Sheils O:
Improved RNA quality and TaqMan Pre-amplification method (PreAmp)
to enhance expression analysis from formalin fixed paraffin
embedded (FFPE) materials. BMC Biotechnol. 8:102008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi Y, Kim A, Kim J, Lee J, Lee SY and
Kim C: Optimization of RNA extraction from formalin-fixed
paraffin-embedded blocks for targeted next-generation sequencing. J
Breast Cancer. 20:393–399. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Győrffy B, Benke Z, Lánczky A, Balázs B,
Szállási Z, Timár J and Schäfer R: RecurrenceOnline: An online
analysis tool to determine breast cancer recurrence and hormone
receptor status using microarray data. Breast Cancer Res Treat.
132:1025–1034. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vermeulen J, Derveaux S, Lefever S, De
Smet E, De Preter K, Yigit N, De Paepe A, Pattyn F, Speleman F and
Vandesompele J: RNA pre-amplification enables large-scale RT-qPCR
gene-expression studies on limiting sample amounts. BMC Res Notes.
2:2352009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Devonshire AS, Elaswarapu R and Foy CA:
Applicability of RNA standards for evaluating RT-qPCR assays and
platforms. BMC Genomics. 12:1182011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park EH, Min SY, Kim Z, Yoon CS, Jung KW,
Nam SJ, Oh SJ, Lee S, Park BW, Lim W, et al: Basic facts of breast
cancer in Korea in 2014: The 10-year overall survival progress. J
Breast Cancer. 20:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hwang KT, Kim EK, Jung SH, Lee ES, Kim SI,
Lee S, Park HK, Kim J, Oh S and Kim YA: Korean Breast Cancer
Society: Tamoxifen therapy improves overall survival in luminal A
subtype of ductal carcinoma in situ: A study based on nationwide
Korean Breast Cancer Registry database. Breast Cancer Res Treat.
169:311–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cronin M, Sangli C, Liu ML, Pho M, Dutta
D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical
validation of the Oncotype DX genomic diagnostic test for
recurrence prognosis and therapeutic response prediction in
node-negative, estrogen receptor-positive breast cancer. Clin Chem.
53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mariotto A, Feuer EJ, Harlan LC, Wun LM,
Johnson KA and Abrams J: Trends in use of adjuvant multi-agent
chemotherapy and tamoxifen for breast cancer in the United States:
1975–1999. J Natl Cancer Inst. 94:1626–1634. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Buchholz TA, Stivers DN, Stec J, Ayers M,
Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, et al:
Global gene expression changes during neoadjuvant chemotherapy for
human breast cancer. Cancer J. 8:461–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fisher B, Dignam J, Wolmark N, DeCillis A,
Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN,
et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen
receptor-positive breast cancer. J Natl Cancer Inst. 89:1673–1682.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner R, Walker M, Watson D, Park T, et al: Multi-gene
RT-PCR assay for predicting recurrence in node negative breast
cancer patients-NSABP studies B-20 and B-14. Breast Cancer Res
Treat. 82:10–11. 2003.
|
|
34
|
Jessup JM, Lively TG and Taube SE: Program
for the Assessment of Clinical Cancer Tests (PACCT): Implementing
promising assays into clinical practice. Expert Rev Mol Diagn.
5:271–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsoi DT, Inoue M, Kelly CM, Verma S and
Pritchard KI: Cost-effectiveness analysis of recurrence
score-guided treatment using a 21-gene assay in early breast
cancer. Oncologist. 15:457–465. 2010. View Article : Google Scholar : PubMed/NCBI
|
